Medicare drug decision will have major impact on older women

The White House on Nov. 6 reached a deal with Eli Lilly and Novo Nordisk to expand Medicare coverage and cap co-payments for their GLP‑1 obesity drugs Zepbound and Wegovy at no more than $50 a month for eligible beneficiaries beginning mid next year; the move targets widespread access barriers given these drugs’ high retail costs (patients now face roughly $500/month in some Medicare cases or more than $1,000/month if self‑pay). The policy is aimed at millions of older Americans—more than 100 million adults are obese and roughly two‑thirds of Medicare beneficiaries are overweight or obese, with obesity rates of about 46% for women 65–74 and 36% for women 75+—who have been priced out of treatment. CMS Director Dr. Mehmet Oz argued broader access could lower taxpayer costs by reducing downstream expenses from obesity‑related conditions, though patients typically require ongoing maintenance dosing to sustain weight loss.

Analysis

The White House announced on Nov. 6 a deal with Eli Lilly and Novo Nordisk to expand Medicare coverage for GLP‑1 obesity drugs Zepbound and Wegovy and to cap co‑payments for eligible Medicare beneficiaries at no more than $50 per month beginning in mid next year. Today many Medicare recipients face out‑of‑pocket co‑payments starting around $500 monthly and self‑pay patients can pay over $1,000 monthly, while patients generally require ongoing maintenance dosing to sustain weight loss.

GLP‑1 receptor agonists address a large addressable population: more than 100 million American adults are obese and roughly two‑thirds of Medicare beneficiaries are overweight or obese (34% obese; 35% overweight), with obesity rates among women 65–74 at about 46% and 36% for women 75+. A meaningful reduction in patient cost shares for eligible seniors could materially expand uptake and create durable, recurring revenue given maintenance therapy requirements.

CMS Director Dr. Mehmet Oz frames the move as taxpayer savings by reducing downstream costs from heart disease, diabetes and renal failure, but the policy’s benefit hinges on eligibility rules and implementation timing because Medicare currently does not cover weight‑loss‑only use. Market signals are moderately positive for LLY and NVO (per‑ticker sentiment ~0.6) and the measured market impact score (~0.35) suggests favorable but not runaway equity reactions; execution, eligibility limits and political or fiscal pushback remain principal risks.

Key Decisions for Investors

• Consider increasing selective exposure to LLY and NVO ahead of mid‑next‑year implementation to capture potential volume upside from expanded Medicare coverage and a $50 monthly co‑pay cap, while keeping position sizes measured for execution risk
• Monitor CMS guidance and company disclosures on eligibility criteria and rollout timelines closely because actual patient uptake will depend on which beneficiaries qualify and on coverage mechanics for maintenance dosing
• Use hedging strategies or staggered purchases to protect against implementation delays, restrictive eligibility or policy reversals given Medicare’s current exclusion of weight‑loss‑only coverage
• Track near‑term prescription fill trends and monthly revenue indicators from both companies and reposition if lower patient cost shares do not translate into sustained volume growth